ExCellThera is a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel curative therapies.
ExcellThera was created following the discovery of a promising molecule (UM-171) for the treatment of blood diseases such as leukemia, lymphatic system cancers, and other bone marrow cancers. Identifying this molecule, which was done in collaboration with IRIC’s Drug Discovery Unit, earned Dr. Guy Sauvageau Radio-Canada’s Researcher of the Year title.
ExcellThera has developed cutting-edge technology – ECT-001 – which combines the UM171 molecule with an optimized cell culture system to provide safe, single-dose treatment for patients with advanced blood cancers and other blood disorders. The Phase I/II study showed promising results.
In addition to its innovative technology, the Company is now developing several preclinical programs involving gene therapy, solid organ tolerization, stem cell mobilization, platelet production, adult tissue regeneration, and antineoplastic agents.
The Quebec government recently awarded $6 million to ExcellThera to conduct clinical studies and ensure that its headquarters remain in Quebec.
